Vanguard Group Inc. grew its stake in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 1.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,684,859 shares of the company's stock after purchasing an additional 145,078 shares during the period. Vanguard Group Inc. owned approximately 3.23% of Bausch Health Companies worth $94,460,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Tobam grew its holdings in shares of Bausch Health Companies by 10.4% during the fourth quarter. Tobam now owns 15,034 shares of the company's stock valued at $121,000 after buying an additional 1,422 shares during the last quarter. American Century Companies Inc. lifted its stake in Bausch Health Companies by 10.6% during the 4th quarter. American Century Companies Inc. now owns 27,236 shares of the company's stock valued at $220,000 after acquiring an additional 2,600 shares in the last quarter. Sanders Morris Harris LLC grew its position in Bausch Health Companies by 16.0% in the 4th quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company's stock worth $234,000 after purchasing an additional 4,000 shares in the last quarter. Kendall Capital Management grew its holdings in shares of Bausch Health Companies by 43.4% in the fourth quarter. Kendall Capital Management now owns 17,995 shares of the company's stock valued at $145,000 after acquiring an additional 5,445 shares in the last quarter. Finally, Principal Securities Inc. increased its position in shares of Bausch Health Companies by 39.7% during the 4th quarter. Principal Securities Inc. now owns 19,220 shares of the company's stock valued at $155,000 after purchasing an additional 5,464 shares during the last quarter. Institutional investors own 78.65% of the company's stock.
Analyst Upgrades and Downgrades
BHC has been the subject of a number of research reports. Jefferies Financial Group reissued a "hold" rating and set a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. Royal Bank of Canada decreased their target price on Bausch Health Companies from $9.00 to $8.50 and set a "sector perform" rating for the company in a research report on Monday, April 7th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $7.17.
Read Our Latest Stock Report on Bausch Health Companies
Bausch Health Companies Stock Up 0.3 %
BHC traded up $0.02 during trading on Tuesday, reaching $4.36. 392,940 shares of the company were exchanged, compared to its average volume of 2,682,974. Bausch Health Companies Inc. has a 12-month low of $3.96 and a 12-month high of $9.85. The company's 50-day moving average is $6.47 and its two-hundred day moving average is $7.51. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -36.30, a P/E/G ratio of 0.37 and a beta of 0.43.
Bausch Health Companies (NYSE:BHC - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). The firm had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.51 billion. Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. Equities analysts forecast that Bausch Health Companies Inc. will post 4.41 earnings per share for the current year.
Bausch Health Companies Profile
(
Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Further Reading
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
